Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
Status:
Unknown status
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The ongoing study is a Phase II, open-label study to evaluate the efficacy of MBP-426 at a
dose of 170 mg/m2 in combination therapy in patients with second line metastatic gastric,
gastro-esophageal junction or esophageal adenocarcinoma.